March 20 (Reuters) - BIOPHYTIS SA:
* FILES FOR ORPHAN DRUG DESIGNATION FOR SARCONEOS IN DUCHENNE MUSCULAR DYSTROPHY (DMD)
* FILED FOR ORPHAN DRUG DESIGNATION WITH THE EUROPEAN MEDICINES AGENCY (EMA)
* A PHARMACOKINETIC PHASE I/II MYODA-PK STUDY TO BE INITIATED IN 2018
* A PHASE II/III EFFICACY STUDY, MYODA-INTEREST, THAT COULD START IN 2019 Source text: bit.ly/2pvTB2z Further company coverage: (Gdynia Newsroom)